Brought to you by:
Silent coronary ischemia: FFRCT reduces cardiac death, myocardial infarction in carotid endarterectomy patients out to three years, study finds
Diagnosis of silent, or unsuspected, coronary ischemia in patients undergoing carotid endarterectomy (CEA) using fractional flow reserve-computed tomography (FFRCT), with selective postoperative coronary revascularization, significantly reduced cardiovascular death, cardiac death and myocardial infarction through three years of follow-up when compared…
FDA grants IDE approval for Selution SLR drug-eluting balloon
MedAlliance’s Selution SLR drug-eluting balloon (DEB) has received investigational device exemption (IDE) approval from the Food and Drug Administration, making it the first limus DEB to be available to U.S. patients, the company announced in a press release. The Selution…
New long-term data of paclitaxel devices continue to show no increased mortality compared to non-drug coated devices
New long-term data from the SAFE-PAD (Safety assessment of femoropopliteal endovascular treatment with paclitaxel-coated devices) study were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions (May 19–22) in Atlanta. The analysis…
Tissue samples show paclitaxel effect in minority of CLTI patients receiving DCB angioplasty, study finds
Paclitaxel effect was witnessed in tissue specimens of a minority of chronic limb-threatening ischemia (CLTI) patients treated with drug-coated balloons (DCBs)—but was not dependent on DCB type, nor the dose level of the drug administered, and was not associated with…
Non-optimal therapy for CLTI ‘more prominent in females’
A real-world claims data analysis of nearly 200,000 patients with chronic limb-threatening ischemia (CLTI) showed that female patients were older, underwent vascular procedures less often, and received guideline-recommended drugs less frequently. However, it also highlighted that female sex was associated with better…
SCAI releases multi-society position statement focused on core competencies for endovascular specialists providing care for CLTI
The Society for Cardiovascular Angiography & Interventions (SCAI) has released a position statement outlining competencies for endovascular specialists who provide care for chronic limb-threatening ischemia (CLTI). The first-of-its-kind document, “SCAI/ACR/APMA/SCVS/SIR/SVM/SVS/VESS position statement on competencies for endovascular specialists providing CLTI care,”…
CLTI, VTE and post-thrombotic syndrome: Leading experts discuss crucial decision-making in interventional approaches
This advertorial is sponsored by ACHL. For Anahita Dua, MBChB, the stark realities and complexities of peripheral arterial disease (PAD) patients undergoing endovascular treatment for chronic limb-threatening ischemia (CLTI) coalesce into one important truth: the necessity of entering the operating…
SCVS 2022: WIfI score does not predict successful healing after transmetatarsal amputation, study finds
A higher initial Wound, ischemia, and foot infection (WIfI) classification score at initial presentation in chronic limb-threatening ischemia (CLTI) patients who underwent a transmetatarsal amputation (TMA) was not associated with a major amputation down the road, according to a retrospective…
PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI patients completes enrollment
Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called “no-option” chronic limb-threatening ischemia (CLTI) patients, the eponymous device maker announced today. “The PROMISE II investigators are…
Cook Medical receives FDA breakthrough designation for new drug-eluting stent
Cook Medical has received Breakthrough Device designation from the Food and Drug Administration (FDA) on a new drug-eluting stent (DES) for below the knee (BTK). This new stent is designed to treat patients suffering from chronic limb-threatening ischemia (CLTI). The Breakthrough…